Brief: Biophytis Updates On Its Phase 2-3 COVA Study On COVID-19

Biophytis SA

22/03/2021 07:24

March 22 (Reuters) - Biophytis SA  ALBPS.PA :
    * BIOPHYTIS GIVES UPDATES ON ITS PHASE 2-3 COVA STUDY ON
COVID-19
    * RECEIVES A FAVORABLE OPINION FROM DMC ON SAFETY OF
SARCONEOS
(BIO101) IN COVA STUDY FOLLOWING FIRST INTERIM ANALYSIS
    * PATIENT ENROLLMENT HAS NOW REACHED 97 OF 155 PLANNED FOR
SECOND
INTERIM ANALYSIS
    * TOTAL OF 28 CLINICAL CENTERS ARE NOW OPENED AND RECRUITING
IN
UNITED STATES, BRAZIL, FRANCE & BELGIUM

Source text for Eikon:  ID:nGNX16mnKm 
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))